Objective: To study antiviral response of efavirenz (EFV)-based antiretroviral therapy (ART) in HIV-1-infected patients who had previously discontinued nevirapine (NVP) and continued the nucleoside reverse transcriptase inhibitor (NRTI) backbone for 7 to 14 days after stopping NVP. Methods: A retrospective cohort study was conducted in patients who discontinued NVP. CD4 count and plasma HIV-1 RNA levels were monitored through 48 weeks of EFV-based regimen. Results: Forty-five patients were eligible with a mean + SD age of 37 + 11 years; 60% were males. Median (interquartile range [IQR]) baseline CD4 count was 43 (19-150) cells/mm 3 and median (IQR) plasma HIV-1 RNA was 5.7 (5.3-5.9) log copies/mL. Median (IQR) duration from stopping NVP to initiating EFV was 13 (7-18) days. At 48 week, 33 (73.3%) of 45 patients achieved plasma HIV-1 RNA <50 copies/mL. At week 12, 24, and 48, median CD4 counts were 193, 238, and 268 cells/mm 3 , respectively (P < .05). No studied risk factor was associated with achieving HIV-1 RNA <50 copies/mL at 48 weeks (P > .05). Conclusion: The strategy of extended short half-life NRTIs in the regimen after discontinuation of NVP is justified.
Introduction
Contemporary antiretroviral therapy (ART), either a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based or a protease inhibitor (PI)-based regimen, has dramatically reduced morbidity and mortality in people living with HIV and AIDS. 1 Although efavirenz (EFV)-based regimen is an NNRTI-based regimen of choice according to recent ART guidelines, 2,3 nevirapine (NVP)-based ART has been widely used in many developing countries. Along with its desired antiviral effects, NVP can cause some unfavorable side effects. Nevirapine should not be restarted after patients have experienced severe adverse reactions. 2 Simultaneous discontinuation of all drugs in an NVP-based regimen, however, may result in functional monotherapy with this drug due to different terminal elimination half-life. In this scenario, viral rebound may occur while NNRTI levels are subtherapeutic over time and then lead to the emergence of NNRTI-associated resistance mutations. A PI should be substituted first for the NNRTI. This PI substitution therapy should then be continued for 2 weeks or a nucleoside reverse transcriptase inhibitor (NRTI) should be continued for a period of time. Although the strategies above seem to be a rational method to reduce the risk of NNRTI resistance, the data regarding efficacy of a subsequent EFV-based regimen after discontinuation of a NVP-based regimen with staggered NRTI components in the real clinical practice are limited. (5) subsequently received EFV-based regimen. The patients were excluded if: (1) the baseline serum creatinine was >2.0 mg/L, (2) the baseline aminotransferase was >5 times the upper normal limit, and (3) they were receiving any PI. All patients were classified into 2 groups based on whether plasma HIV-1 RNA was <50 copies/mL at week 48.
Methods
The objective was to study antiviral response and tolerability of EFV-based ART in HIV-1 infected patients who had previously discontinued NVP, continued the NRTI backbone for 7 to 14 days after stopping NVP, and subsequently received EFV-based regimen. The primary outcome of interest was the proportion of patients who achieved plasma HIV-1 RNA <50 copies/mL at 48 weeks. The secondary outcomes were as follows: (1) to study the increment of the number of CD4 counts at 48 weeks of ART from baseline value and (2) to study possible predicting factors for achieving plasma HIV-1 RNA <50 copies/mL at 48 weeks of ART. CD4 counts were measured by flow cytometry and HIV-1 RNA viral loads were measured by Roche Amplicor version 1.5 (Roche Diagnostics, Branchburg, New Jersey). Treatment failure was defined as either a rebound plasma HIV-1 RNA of >50 copies/mL after having previously undetectable value or a lack of achievement to <50 copies/mL at 24 weeks of ART or discontinued EFV due to any reasons.
Mean (+SD), median (interquartile range [IQR]), and frequencies (%) were used to describe patients' characteristics in both groups. Fisher exact test and Mann-Whitney U test were used to compare categorical variables and continuous variables between the 2 groups, respectively. Paired t test was used to compare CD4 between each time point. Binary logistic regression model was used to determine the possible risk factors for treatment failure at 48 weeks. A 2-sided P value of less than .05 was considered statistically significant. All analyses were performed using Statistical Package for the Social Sciences (SPSS) software version 11.5 (SPSS Inc, Chicago, Illinois).
Results
There were 45 patients, of whom 60% were male. Baseline characteristics of all patients and between the 2 groups are shown and compared in Table 1 . Median (IQR) time from stopping NVP to initiating EFV was 13 (7-18) days. In all, 40 (88.9%) and 5 (11.1%) patients received d4T/3TC and ZDV/ 3TC for their NRTI backbones, respectively. Of all, 35 (77.8%), 5 (11.1%), and 5 (11.1%) patients discontinued NVP due to skin rashes grade II to III, hepatitis, and both, respectively. The patients who experienced treatment failure at week 48 had a higher baseline plasma HIV-1 RNA than those who achieved undetectable plasma HIV-1 RNA (P ¼ .047). At 48 weeks of EFV-based ART, 33 (73.3%) of 45 patients achieved plasma HIV-1 RNA <50 copies/mL. Median CD4 counts were 193, 238, and 268 cells/mm 3 at 12, 24, and 48 weeks, respectively. By repeated measurement analysis, there were differences in CD4 counts between each time point from baseline value (P < .05). Binary logistic regression analysis of possible risk factors, including baseline log plasma HIV-1 RNA, time from stopping NVP to initiating EFV, gender, baseline CD4 counts, and baseline alanine aminotransferase (ALT), showed that no studied risk factor was associated with achieving plasma HIV-1 RNA <50 copies/mL at 48 weeks of EFVbased ART (P > .05). A total of 12 patients discontinued EFV-based ART. The reasons were as follows: 5 (41.7%) patients were lost to follow-up, 3 (25.0%) had virological failure, 2 (16.7%) were transferred to other hospital, 1 (8.3%) had EFV-related skin reaction, and 1 (8.3%) had EFV-related neurological event. Three patients with virological failure had plasma HIV-1 RNA <1000 copies/mL.
Discussion
The reported half-life of NVP is 45 hours after receiving a single dose and 25 to 30 hours after receiving multiple doses. 4 The difference in termination half-life of NVP between single dose and steady state is a result of autoinduction of cytochrome P450 enzymes in the liver. However, either ongoing HIV replication occurs after single-dose mother-to-child transmission prevention or HIV rebound occurs during low drug exposure, NNRTI-associated mutations may emerge. Herein, the duration of receiving NVP before discontinuation was 17 days; therefore, receiving an additional staggered period of dual short half-life NNRTIs for 7 to 14 days to cover NVP tail could be an appropriate strategy. However, prolonged extension of the use of the NRTI component may also increase the risk of emergence of NRTI-resistant virus, particularly in patients with fast drug elimination. To date, the additional data for standard recommendation continuing dual NRTI components are still required. The British HIV Association (BHIVA) guidelines recommend continuing the dual NRTIs for 7 days after discontinuing NNRTIs. 2 A recent study in Africans showed that 7 to 10 days with dual NRTI cover is suitable due to short elimination of NVP. 5 However, several factors may affect the elimination of NVP after drug discontinuation, such as ethnic group, body weight, gender, age, liver function 6 as well as concurrent drug use. Cytochrome P450 2B6 isoenzyme has been reported to influence not only EFV but also NVP. 7 In the current study, none of the studied factors was associated with treatment failure at 48 weeks of EFV-based ART in the multivariate analysis (P > .05). Moreover, virological and immunological responses after 48 weeks of EFV-based ART are favorable. Three patients developed treatment failure due to detectable plasma HIV-1 RNA. Our results in these particular patients are consistent with a previous study that was conducted in patients who received EFV as a first-line antiretroviral (ARV) regimen. 8 However, long-term antiviral response should be followed. Of note, a previous study showed that the staggered period of NRTI component alone may fail to prevent the selection of NNRTIassociated mutations. 9 The fluctuation in plasma NNRTI concentration before drug discontinuation due to poor drug adherence 9 and acquired drug resistance may be explained. Hence, the importance of strict adherence to medication dosing must be emphasized to minimize the risk of treatment failure.
In conclusion, the efficacy of a subsequent EFV-based regimen in patients who continued 7 to 14 days of an NRTI backbone after discontinuation of NVP is favorable. Most of the patients tolerated EFV well. The strategy of using extended short half-life NRTIs in the regimen after discontinuation of NVP is justified. However, future prospective study should be conducted to confirm this result. .374 Duration from stopping nevirapine to initiating efavirenz (days), median (IQR) 13 (7-18) 12 (7-21) 14 (9-16) .560
Abbreviations: IQR, interquartile range; ALT, alanine aminotransferase. a Included patients who had plasma HIV-1 RNA >50 copies/mL and stopped the study drug for failure, side effects, or any other reasons.
